Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 8/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8634451 | 0.88 | FEN1 (0.59) | MEN1KMT2ASMN1; SMN2FEN1LMNA | |
| SCHEMBL10661343 | 0.88 | CES2 (0.48) | MEN1KMT2ASMN1; SMN2RAB9APOLB | |
| SCHEMBL27818410 | 0.82 | CA12 (0.52) | MEN1KMT2ASMN1; SMN2LMNARAB9A | |
| SCHEMBL25674002 | 0.81 | CES2 (0.41) | MEN1KMT2ASMN1; SMN2LMNARAB9A | |
| SCHEMBL30310798 | 0.81 | CES2 (0.41) | MEN1KMT2ASMN1; SMN2LMNARAB9A | |
| SCHEMBL8634360 | 0.80 | FEN1 (0.54) | MEN1KMT2ASMN1; SMN2FEN1LMNA | |
| SCHEMBL946028 | 0.80 | LMNA (0.55) | MEN1KMT2ASMN1; SMN2GAALMNA | |
| SCHEMBL6462215 | 0.80 | MEN1 (0.56) | MEN1KMT2AGAAFEN1LMNA | |
| SCHEMBL16563920 | 0.78 | MEN1 (0.52) | MEN1KMT2ASMN1; SMN2GAAFEN1 | |
| SCHEMBL28359096 | 0.77 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2GAAFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| CN-101400657-B | Polycyclic cinnamamide derivative | ESAI R & D MAN CO LTD | 2012-05-30 | — | — | CN | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| CN-101400657-A | Polycyclic cinnamamide derivative | ESAI R & D MAN CO LTD (JP) | 2009-04-01 | — | — | CN | disclosed |
| EP-1732541-A4 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| EP-1732541-A2 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005099688-A2 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | MEN1 860/4885KMT2A 983/4885SMN1; SMN2 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.